SCHEMBL17407883

SCHEMBL17407883

Nc1ccc(C(F)(F)F)nc1-c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 8/20 0.47
FFAR4 Q5NUL3 1/20 0.42
ALPI P09923 1/20 0.40
PTGS2 P35354 2/20 0.39
NOD1 Q9Y239 1/20 0.39
KDM4E B2RXH2 1/20 0.38
PTGS1 P23219 1/20 0.38
NISCH Q9Y2I1 1/20 0.38
CHRNA7 P36544 1/20 0.38
SCN2A Q99250 3/20 0.38
SCN1A P35498 2/20 0.38
CYP1A2 P05177 2/20 0.37
SCN9A Q15858 2/20 0.37
TDP2 O95551 1/20 0.37
ADORA2A P29274 1/20 0.37
NPC1 O15118 1/20 0.37
GMNN O75496 1/20 0.37
USP2 O75604 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15330682 0.78 SCN5A (0.44) SCN5AALPIPTGS2NISCHSCN2A
SCHEMBL17393487 0.76 KCNH2 (0.50) KCNH2
SCHEMBL22211497 0.75 PTGS2 (0.35) PTGS2KDM4EADORA2AHSD17B10KCNH2
SCHEMBL17407882 0.73 POLB (0.48) KDM4ESCN9ACYP3A4CYP2C9SCN10A
SCHEMBL16068077 0.72 HDAC4 (0.51) PTGS2KDM4ENPC1LMNACYP2C9
SCHEMBL23618148 0.71 SCN5A (0.49) SCN5AALPIKDM4ENISCHCHRNA7
SCHEMBL5315316 0.71 NOTUM (0.41) SCN5ANISCHCHRNA7SCN2ASCN1A
SCHEMBL24024734 0.69 MEN1 (0.54) SCN5AFFAR4KDM4ENISCHSCN2A
SCHEMBL23618149 0.69 MPL (0.55) SCN5AKDM4ENISCHSCN2ASCN1A
SCHEMBL7708933 0.68 AURKA (0.46) SCN5ANISCHSCN2ACYP1A2SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2975030-B1 DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2020-07-15 EP disclosed
US-9499553-B2 Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-22 US disclosed
US-9499553-B2 Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-22 US disclosed
US-20160002251-A1 DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-01-07 US disclosed
US-20160002251-A1 DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002251-A1 DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME SLC9A5, SLC5A2, SLC5A1 SCN5A 58/4885FFAR4 1752/4885ALPI 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.